HC Wainwright Reiterates Buy Rating for BioCardia (NASDAQ:BCDA)

HC Wainwright reiterated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

BioCardia Price Performance

Shares of BCDA stock traded down $0.01 during trading on Wednesday, hitting $1.99. 99,090 shares of the stock traded hands, compared to its average volume of 272,649. BioCardia has a 52-week low of $1.63 and a 52-week high of $10.79. The firm has a market capitalization of $9.12 million, a P/E ratio of -0.48 and a beta of 1.25. The firm’s fifty day moving average price is $2.32 and its 200-day moving average price is $2.77.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.